摘要
目的探讨血清SP-A、SP-D在放射性肺损伤患者疾病发展过程中的临床意义。方法选择2008年11月~2014年8月在黑龙江省医院南岗院区接受放疗的肺癌患者60例,其中放疗后1周时未出现放射性肺损伤者30例为N组,放疗后1周出现放射性肺损伤者30例为R组。分别于放疗后第1周对患者予以晨起静脉采血,采用酶联免疫吸附法（ELISA）检测血清SP-A、SP-D水平,R组于放疗后第1周、第3周、第3个月及第6个月检测血清SP-A、SP-D水平。结果 N组、R组患者血清SP-A、SP-D的水平比较,差异有高度统计学意义（P〈0.01）。R组患者血清SP-A、SP-D的水平4个不同时间点两两比较,差异有高度统计学意义（P〈0.01）。结论 SP-A、SP-D伴随放射性肺损伤病程进展而变化,联合监测可以是判断疾病严重程度的指标之一。
Objective To study the clinical significance of serum SP-A and SP-D in the development of radiation pulmonary injury（RP）. Methods From November 2008 to August 2014, in Nangang Branch of Heilongjiang Hospital, 60 lung cancer patients with radiotherapy were selected, 30 patients occured RP 1 week after radiotherapy were as group R,30 patients did not occur RP 1 week after radiotherapy were as group N. 1 week after radiotherapy, all patients were collected the venous blood specimen in the morning, SP-A and SP-D in serum were detected by ELISA, patients in group R were detected SP-A and SP-D in serum at 1st week, 3rd week, 3rd month, 6th month. Results SP-A and SPD in serum of two groups were compared, the differences were statistically significant（P〈0.01）. SP-A and SP-D in serum of patients in group R at 4 different time points were compared, the differences were statistically significant（P〈0.01）. Conclusion SP-A and SP-D change with development of RP, combined detection might be one of valuable index predicting the severity of RP.
出处
《中国医药导报》
CAS
2016年第14期100-102,106,共4页
China Medical Herald
基金
黑龙江省科学基金项目(GC08C422)
